Witness Name: Glenn Wilkinson

Statement No.: WITN2050001

Exhibits: WITN2050002 – WITN2050114

Dated: 14 August 2020

INFECTED BLOOD INQUIRY

EXHIBIT WITN2050043

TWO CONFLICTING REPORTS OF THE SAME MEETING COVERING ETHICS, TESTING, TRIALS AND PUPS

File

(2595)

OXFORDSHIRE HEALTH AUTHORITY

OXFORD HAEMOPHILIA CENTRE

Tel: Oxford (0865) 64841
Ext.

Churchill Hospital,
Headington,
Oxford OX3 7LJ.

2 COMPLETE DIFFERENT SET OF MINUTES (SAME MEETING)

20th May, 1983

To: All Reference Centre Directors

ETHICS - TESTING TRIALS.

PUPS.

re: Special Meeting of Haemophilia Reference Centre Directors

Please find enclosed Minutes of the above meeting held on 13th May, 1983 at St. Thomas' Hospital.

Yours sincerely,

ENC.

F4

(2596)

UP-DATE ON AIDS

1. Aids in Haemophiliacs in the UK

There is one suspect case in Cardiff. Although CDSC states that this case meets the USA criteria for AIDS, the clinician in charge does not consider that it should be regarded as a confirmed case. There is also a possible case at Bristol Royal Infirmary but it may not meet all the criteria. Further details are being sought. There is still no trace of the London case which was mentioned in the press.

2. Recommendations of Haemophilia Reference Centre Directors

At their meeting on 13 May 1983, the Haemophilia Reference Centre Directors agreed that on the evidence available and because of the benefits of treatment, no restriction should be placed on the use of imported Factor VIII concentrate other than to continue with the present policy of using only NHS material for children under the age of 4 years and for mild haemophiliacs

3. Action proposed by Regional Transfusion Directors

At their meeting on 18 May 1983 the Regional Transfusion Directors agreed to prepare an information leaflet on AIDS which would be available for donors to read at donor sessions and could be sent to donors phoning in with enquiries. (Directors asked if the Department would pay for the printing of such a leaflet and this is being discussed with Information Division.)

The Directors further proposed to make an approach to the Medical Gay Society (an association of homosexual doctors) to enlist their help in the dissemination of information on AIDS to homosexual groups.

Directors were adamant that there would be no direct questioning of donors about their sexual habits nor about the presence of symptoms such as night sweats, weight loss etc.

4. FDA regulations on donor screening

As from 23 March 1983, FDA regulations have required that:

1) Educational programmes be instituted for potential donors from defined high risk groups asking that they refrain from donation. (High risk groups are defined as: persons with symptoms and signs suggestive of AIDS; sexually active homosexual or bisexual men with multiple partners; Haitian immigrants; intravenous drug abusers and sexual partners of individuals at increased risk of AIDS.)

CODE 58-77

ii) All plasma donors to receive information on AIDS.

iii) Plasma taken from a donor in a high-risk group should be labelled to indicate that it should only be used in the preparation of albumin, PPF, globulin or for non-injectable products. (NB: the use of such plasma for albumin, PPF etc production is extremely dubious. If an infectious agent is involved, there is no means of knowing that the heat treatment, to which these products are subjected, will inactivate it - DW.)

iv) The donor's medical history should include specific questions designed to detect possible AIDS symptoms eg night sweats, unexpected weight loss etc.

v) Donors should be examined for lymphadenopathy (a limited examination to be made by "an adequately trained individual" at each donation and annually by a physician).

vi) The donor's weight should be recorded before each donation. A donor with unexplained weight loss should be referred to a physician and any plasma stored from that donor should be quarantined.

vii) Plasma from a donor known or suspected to have AIDS must be quarantined and destroyed or otherwise handled according to specified procedures for bio-hazardous materials.

5. Relevance of FDA regulations for UK imports

A disproportionately high percentage of plasma from "high-risk" donors is likely to find its way into imported albumin, PPF and gamma globulin preparations on the totally unsubstantiated premise that heat-treatment of these products will inactivate the AIDS agent. Medicines Division will presumably be considering the implications of this.

There are presumably large stocks of Factor VIII concentrates in the USA prepared before the 23 March guidelines came into force. It is possible that concentrates made from the "safer" plasma may be retained for use in the USA while the older stocks may be dumped on export markets such as the UK. Medicines Division has been asked to consider if there is any way - perhaps by means of new labelling requirements - to prevent this.

Medicines Division have also been asked to consider whether it would be possible to identify products manufactured from plasma taken outside the areas where AIDS is most prevalent eg New York, San Francisco, Los Angeles etc and whether it would be feasible - in terms of the amount of material currently available - to restrict imports of Factor VIII concentrate to those batches made from plasma collected after 23 March.

As a long stop, Immuno or other European manufacturers could be asked if they would be able to supply up to 30 million i.u. of Factor VIII made wholly from European plasma. Presumably Supply Division would wish to take the lead on this.

6. Implications of the introduction of heat-treated Factor VIII concentrates

A number of commercial manufacturers of Factor VIII are hoping to introduce Factor VIII concentrates which have undergone an additional heat-treatment step which is designed to reduce viral infectivity. Although originally

aimed at reducing the risk of transmission of hepatitis, it is now being suggested that heat-treated concentrates might also reduce the risk of the transmission of AIDS.

As far as I am aware, there have been no controlled clinical trials to substantiate a reduced hepatitis risk from the heat-treated concentrates and nor, of course, is there any information on the transmission of AIDS. Nevertheless, should they be licensed for use in this country, it seems more than likely that there will be a heavy clinical demand for them. Not only would this have cost implications for the NHS, since the heat treatment substantially reduces the yield of Factor VIII per litre of plasma and therefore increases production costs, but the BPL may find itself obliged to manufacture heat-treated concentrates for which up to 60% more plasma might be needed simply to produce the current output of Factor VIII.

Clearly, there is a need for a controlled clinical trial of heat-treated concentrates in respect of hepatitis infectivity. However, such a trial could pose ethical problems at the present time. In earlier discussions on a protocol for such a clinical trial, Haemophilia Centre Directors had been of the opinion that a meaningful trial could only be conducted in patients who had not previously been treated with Factor VIII ie newly diagnosed mild haemophiliacs. However, this is a particular group of patients for whom the Directors have recommended (see para 2 above) that only NHS material should be used.

7. Genetically engineered Factor VIII

The prospects for genetically engineered Factor VIII still seem to be several (5-10) years in the future.

MED SEB

20 May 1983

190

MINUTES OF SPECIAL MEETING OF HAEMOPHILIA REFERENCE CENTRE DIRECTORS held at ST. THOMAS HOSPITAL on 13.5.83, at 11.00 a.m.

Present: Professor A.L. Bloom (Chairman)
Dr. John Craske
Dr. Peter Hamilton
Dr. Peter Kernoff
Dr. Christopher Ludlam
Dr. Geoffrey Savidge
Dr. Eric Preston
Dr. Irvine Delamore
Dr. C.R. Rizza
Dr. Diane Walford (D.H.S.S. observer)

Apologies for absence received from Dr. Elizabeth Mayne

Professor Bloom briefly outlined the background to the meeting and its purpose. The recent publicity in the press, radio and television about the problem of acquired immuno deficiency syndrome (AIDS) had caused considerable anxiety to haemophiliacs and their medical attendants as well as to the Department of Health. There was clearly a need for Haemophilia Centre Directors to discuss what should be done with regard to the surveillance and reporting of suspected cases and the management of patients. To date in the United Kingdom one haemophiliac is suspected of suffering from AIDS. In London there are reported to be 10 cases of confirmed AIDS in homosexual males. Concern was expressed about the definition of AIDS. It was felt that there might be many individuals with evidence of impaired cell-mediated immunity but only a very small number of these might progress to a full-blown picture of the condition. It is important that such individuals are not classified as suffering from AIDS. It was

accepted that because of our lack of knowledge of the nature of AIDS, decisions about diagnosis and reporting of suspected cases would prove difficult. Nevertheless the criteria laid down by the Centres for Disease Control, Atlanta, Georgia, and in the form prepared by Dr. J. Craske for use at U.K. Haemophilia Centres, should be followed for diagnostic purposes. The importance of opportunistic infection as a diagnostic criterion was stressed. It was agreed that any patient who was suspected of suffering from AIDS should be reported immediately on the form provided and thereafter the clinical course of the patient would be followed and a definitive diagnosis attached if the patient developed intractable disease.

The steps to be taken should a patient develop the features of the full-blown condition were then discussed. It was agreed that there was insufficient information available from the U.S. experience to warrant changing the type of concentrate used in any particular patient. Moreover once the condition is fully developed it seems to be irreversible so that there would seem to be no clinical benefit to be gained by changing to another type of factor VIII.

With regard to general policy to be followed in the use of factor VIII concentrates, it was noted that many directors have up until now reserved a supply of National Health Service concentrates for children and mildly affected haemophiliacs and it was considered that it would be circumspect to continue with that policy. It was also agreed that there was, as yet, insufficient evidence to warrant restriction of the use of imported concentrat in other patients in view of the immense benefits of therapy. Th

192

situation shall be kept under constant review.

It was noted that the Blood Transfusion Centre Directors were due to meet to discuss the problem of donor screening in relation to AIDS. The news of this meeting was welcomed by the Haemophilia Reference Centre Directors.

There being no further business the meeting closed at 2.15 p.m.